1-3 of 3
Ian Prosser
Close
Sort by
Journal Articles

The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).

Melita K Kenealy, MBBS, FRACP, FRCPA, John F Seymour, MBBS, PhD, FRACP, Cowan Linda, Alvin Milner, Pratyush Giri, Shir-Jing Ho, MBBS, FRACP, FRCPA, Warwick Benson, Andrew Nicol, MBBS, FRCPA, FRACP, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Craig Underhill, MBBS, FRACP, Ilona Cunningham, Anthony K. Mills, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Peter Presgrave, MBBS, FRACP, FRCPA, PhD, Robin Filshie, MBChB, FRACP, FRCPA, PhD
Journal: Blood
Blood (2009) 114 (22): 1749.
https://doi.org/10.1182/blood.V114.22.1749.1749
Published: 2009
Journal Articles

A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.

Jesús F. San-Miguel, MD, PhD, Orhan Sezer, MD, PhD, David Siegel, Andreas Guenther, MD, Maria-Victoria Mateos, MD, PhD, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Michele Cavo, MD, Joan Blade, MD, Mario Boccadoro, MD, Bourras R. Bengoudifa, Martin Klebsattel, PhD, Priscille M. Bourquelot, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 3852.
https://doi.org/10.1182/blood.V114.22.3852.3852
Published: 2009
Journal Articles

A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma

Davi d Siegel, Orhan Sezer, Jesus F. San Miguel, Maria-Victoria Mateos, Ian Prosser, Michele Cavo, Muhammad Jalaluddin, Katharine Hazell, Priscille M. Bourquelot, Kenneth C. Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 2781.
https://doi.org/10.1182/blood.V112.11.2781.2781
Published: 2008